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1607-551X/Copyright ª 2015, KaohsiuAbstract Immunotherapy using bacille Calmette-Guerin (BCG) instillation is the mainstay
treatment modality for superficial urothelial cancer (UC) through toll-like receptor (TLR) acti-
vation of cognitive immune response. We investigated the roles of TLR7 in the activation of
apoptosis in UC cells after BCG treatment. The in vitro cytotoxicity effect of BCG on UC cells
was measured by a modified 3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyl tetrazolium assay. Ex-
pressions of TLR7 mRNA and protein in native UC cells prior to and after BCG treatment were
analyzed using real-time quantitative polymerase chain reaction and western blot methods.
Phagocytotic processes after BCG treatment in UC cells were observed microscopically using
a specific immunostain, subsequent cellular apoptosis-related signals induced by TLR7 were
analyzed by western blot. Low-grade UC cells, TSGH8301, showed significant cellular death
(4.23-fold higher than the high-grade UC cells T24 and J82) when treated with BCG and the
BCG cytotoxicity was displayed in a doseetime-dependent manner. TSGH8301 cells had the
highest content of TLR7 mRNA, 7.2- and 4.5-fold higher than that of T24 and J82 cells, respec-
tively. TLR7 protein expression was also significantly increased in TSGH8301 cells.
Phagocytosis-related markers, including beclin 1, ATG2, and LC3, were increased when
TSGH8301 cells were treated by BCG. Interleukin-1 receptor-associated kinases 2 and 4 were
also increased markedly in TSGH8301 cells. On the contrary, cellular apoptosis of TSGH8301
cells decreased by 34% when TLR7 activation was suppressed by the TLR antagonist IRS661 af-
ter BCG treatment. Our findings suggest that well differentiated TCC cells have highereclare no conflicts of interest.
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Urothelial cancer (UC) of thebladder accounts for about 4%of
all cancer-related deaths. A large majority of tumors (80%)
are superficial at diagnosis, and have a high rate of local
recurrence (70%) and progression (30%) after local surgical
interventions. Bacille Calmette-Guerin (BCG) has been shown
to eliminate tumors and prevent recurrences of bladder UC
with routine complete response rates of 60e70% [1,2].
Despite its well-recognized clinical efficacy, many questions
about its precise mechanism of action remain unanswered.
The primary mechanism of the antitumor effect of BCG
was that it induced an immune response, preferentially a
Th1-polarized response characterized, by the production of
elevated levels of interleukin-12 and interferon -g [3,4].
Recent studies have demonstrated activation of toll-like
receptors (TLRs) in immune responsive cells after BCG
instillation. Downstream substrates of TLRs recruit other
immune cells, suggesting that TLRs play a key role in the
antitumor response to BCG therapy [5,6]. They provide
essential requirements for initiating T-cell immunity: anti-
gen uptake, processing and presentation by dendritic cells
and other antigen-presenting cells, dendritic cell matura-
tion, and -cell activation [7].
Directly killing of UC cells with BCG may be attributed to
differential expression of the receptors of cytotoxic effector
molecules, including TLRs, on target cells or adhesion mole-
cules on both effector and target cells. These possibilities
need to be investigated. Therefore, to determine the rela-
tionship between TLR expression and the direct killing effect
of BCG on UC cells, we investigated TLR7 expression in BCG-
treated UC cells and demonstrated that TLR7 activation can
directly enhance BCG-induced apoptosis in UC cells.
Materials and methods
Cell culture
High-grade UC cell lines, T24 and J82, were purchased from
ATCC (American Type Culture Collection, Manassas, VA,
USA) and low-grade UC cell lines, TCC9202 and TSGH8301,
established at our laboratory were cultured in an RPMI-1640
medium (Thermo Scientific HyClone, Logan, UT, USA), and
supplemented with 10% fetal bovine serum and antibiotics
in 5% CO2 at 37C.
Chemicals and antibodies
BCG (ImmuCyst 81 mg/vial) and IRS661 (a TLR inhibitor)
were purchased from Sanofi Pasteur Limited (West Toronto,
Ontario, Canada) and Sigma-Aldrich (St Louis, MO, USA),respectively. Antibodies of TLR7, IRAK2/4, caspase 8,
beclin 1, ATG2, LC3, and antirabbit IgG horseradish perox-
idase were obtained from Genetex (Irvine, CA, USA).
Measurement of cytotoxicity of BCG to UC cells
UC cells were exposed to the BCG reagent at concentra-
tions of 0.05 mg/mL, 0.5 mg/mL, and 5 mg/mL. Cellular
chemosensitivity was assayed using a modified 3-(4,5-
dimethylthiazo-2-yl)-2,5-diphenyl tetrazolium (MTT;
Sigma-Aldrich) assay to determine cell viability in vitro [8].
In brief, cells (4000/well) in 100 mL culture medium were
seeded into 96-well microplates and incubated at 37C for
24 hours before drug exposure. The numbers of plated cells
were calculated to keep control of the growth of cells in the
exponential phase throughout the 72-hour incubation
period. At one point, 50 mL of MTT was added to each well
and allowed to react for 3 hours. The blue formazan crys-
tals formed were dissolved in 150 mL of dimethyl sulfoxide.
The optical density was determined by absorbance spec-
trometry at 492 nm using a microplate reader (MRX-2;
Dynex Technologies, Inc., Chantilly, VA, USA). Three sepa-
rate experiments, each run in triplicate, were performed to
obtain the mean cell viability.
Quantitative reverse transcription polymerase
chain reaction assay of TLR7 mRNA
Total RNA was extracted from cultured cells using a
commercially available RNA extraction kit (Trizol; Gibco,
Carlsbad, CA, USA), and cDNA was synthesized with a
reverse transcription kit (Reverse Transcriptase Master Mix;
Roche Diagnostics, Germany). The cDNA was amplified by
quantitative reverse transcription-polymerase chain reac-
tion (PCR) using 2 mL of the LightCycler PCR Master Mix. The
amplicon was detected by fluorescence using a specific pair
of TLR7 primers: 50-CCTTGAGGCCAACAACATCT for sense
and 50-ACAGTAGGGACGGCTGTGAC for antisense. The
mRNA of glyceraldehyde 3-phosphate dehydrogenase with
specific pair primers (50-ACCCACTCCTCCACCTTTGAC for
sense and 50-CATACCAGGAAATGAGCTTGACAA for antisense)
was processed as a housekeeping gene. The fluorescence
emitted after hybridization to the template DNA was
measured by the LightCycler 480 Instrument. All PCR re-
actions were performed for 40 cycles of 60 seconds at 95C,
10 seconds at 60C, and 5 seconds at 72C.
Western blotting analysis of apoptotic signaling
Protein expressions of TLR7, IRAK2/4, caspase 8, beclin 1,
ATG2, and LC3 were measured by the western blot method.
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after BCG treatment (0.05 mg/mL and 0.5 mg/mL) were
loaded onto sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) with 8e12% resolution and 4%
stacking gel. The SDS-PAGE was supplied with a voltage of
90 V for 45 minutes and 120 V for 90 minutes in running
buffer (25 mM Tris, 192 mM glycine, and 0.1% SDS). Proteins
were transferred to a polyvinylidene fluoride (PVDF)
membrane in transfer buffer (25 mM Tris, 192 mM glycine,
pH 8.3, 20% methanol, and 0.025e0.1% SDS) supplied with a
voltage of 100 V at 4C for 1 hour. The membrane was
rinsed and shaken on a 40 rpm shaker in 5% milk in 0.1% Tris-
buffered saline and Tween-20 at room temperature for 1
hour. Then the membrane was rinsed in specific antibodies
at room temperature for 1 hour. After washing, the mem-
brane was rinsed in horseradish peroxidase-conjugated
secondary antibodies for 1 hour. Enhanced chem-
iluminescence signals were collected and analyzed using
the UVP Biospectrum (USA).Figure 1. Cell viability of (A) T24, J82, TCC9202, and
TSGH8301 cells when treated by BCG (0.05e5 mg/mL) for 72
hours and (B) TSGH8301 cells when treated with BCG at
0.05 mg/mL, 0.5 mg/mL, and 5 mg/mL dosages for 12 hours, 24
hours, and 48 hours, respectively. BCGZ Bacille Calmette-
Guerin.Phagocytic assay of BCG in UC cells
Cellular BCG particles were studied by a fluorescence mi-
croscope. Cells were harvested and washed three times
with phosphate-buffered saline after being incubated with
BCG (5 mg/mL) for 24 hours, and stained with 100 mg/mL
DAPI (AO; Sigma-Aldrich) for 10 minutes. b-actin stains
were used to margin the cell bundles. The color distribution
and structure of the cells were then observed under a
fluorescence microscope (Olympus). The phagocytic index
was calculated as the number of ingested BCG per cell [9].Statistical analysis
Data were presented as mean  the standard error of at
least three independent experiments. For comparisons
between three or more groups, two-way analysis of vari-
ance was used, followed by the Student method for mul-
tiple pairwise comparisons. Differences were considered
statistically significant at p < 0.05.Results
Dose-dependent cytotoxicity of BCG to UC cells
Various UC cells were treated with different dosages of BCG
(0.05 mg/mL, 0.5 mg/mL, and 5 mg/mL) for 72 hours. The
results showed that BCG directly inhibited cell growth in a
dose-dependent manner, accounting for 3e5%, 4e7%,
2e25%, and 5e37% inhibition in T24, J82, TCC9202, and
TSGH8301 cells, respectively. TSGH8301 cells showed
significantly higher BCG cytotoxic sensitivity (p Z 0.003)
than T24 cells under the same dosage condition (Figure 1A).
BCG treatment (0.05e5 mg/mL) also showed a cytotoxic
effect on TSGH8301 cells in a time- and dose-dependent
manner, which reduced cell viability by 12%, 25%, and
25e40% at 12 hours, 24 hours, and 48 hours, respectively
(Figure 1B).Higher TLR7 expression in well-differentiated UC
cells
Low-grade UC cells present a higher expression of TLR7
than high-grade UC cells. The increased expression of TLR7
was demonstrated in either the mRNA or protein level, as
shown in Figures 2A and 2B. TSGH8301 cells had a signifi-
cantly higher level of TLR7, 2.5- and 13.2-fold higher
compared with T24 and J82 UC cells (pZ 0.003 and 0.014).
Furthermore, BCG treatment for 48 hours could enhance
the expression of TLR7 in UC cells even when the BCG
dosage was as low as 0.5 mg/mL, and TSGH8301 cells had
the highest expression level of TLR 7, which was 4.1-fold
higher than that of other UC cells (p Z 0.005) (Figure 2C).
Phagocytotic activities increased in UC cells
through TLR7 activation after BCG treatment
TSGH8301 cells were selected for further analysis since
they had a higher expression of TLR7. The phagocytic ac-
tivity of BCG-stimulated TSGH8301 cells increased mark-
edly from 6 hours to 24 hours after treatment (p Z 0.05)
(Figure 3A). As shown in Figures 3BeE, phagocytosis-related
factors, including beclin 1, ATG2, and LC3, were all upre-
gulated in TSGH8301 cells after BCG treatment. Beclin 1
displayed a 3.9-fold increase compared with the control
group. It also significantly increased (1.2-fold) 24 hours
after stimulation with a lower dosage of BCG (0.05 mg/mL),
but a reverse change was seen in the case of a higher-
Figure 2. Relative expression of (A) mRNA and (B) protein fold change of TLR7 in T24, J82, TCC9202, and TSGH8301 cells. (C)
Changes of TLR7 in T24, J82, TCC9202, and TSGH8301 cells after BCG stimulation (0.5 mg/mL) at 48 hours. All experiments were
repeated three times. BCGZ Bacille Calmette-Guerin; TLR Z toll-like receptor.
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ATG2 and LC3 showed similar increasing results to beclin 1
with BCG treatment regardless of the dosage used
(Figure 3B), ATG2 increased 1.3-fold compared with the
control group at 24 hours, and LC3 increased significantly
(2.6-fold) at 12 hours when stimulated by a higher dosage of
BCG (p Z 0.03) (Figures 3C and 3D). IRAK2/4, TLR7 down-
stream regulators, were significantly increased (2.5- and
4.2-fold, respectively; p Z 0.001) after treatment with a
higher dosage of BCG for 12 hours. The same finding was
noted with caspase 8 when a significant maximum increase
was observed at 12 hours (p Z 0.006) (Figures 3E and 3F).
Changes of TLR7 in UC cells induced by BCG
treatment was inhibited by IRS661 TLR7 antagonist
Increased TLR7 in TSGH8301 cells after 24 hours of BCG
treatment was significantly suppressed to the basic level, as
the cells were controlled by IRS661 treatment (p Z 0.001)
(Figure 4).
Discussion
Cell response to mycobacteria has been shown to depend on
TLR signaling. BCG can stimulate various types of TLRs by
different mycobacterial components with secondary inflam-
matory reaction, such as lipopolysaccharides (LPS) canstimulate TLR1 and TLR4 [10], and BCGDNAor RNA strains can
stimulateTLR7andTLR9expression [11]. TLR4 is also involved
in the response to mycobacteria, and an in vitro study on
human epithelial cells showed that BCG induced activation of
the ERK1/2 MAPK pathway and secretion of interleukin-8 via
both TLR2 and TLR4 signaling [12]. TLR4 signaling is required
for the development of a Th1 response that can increase
lymphocyte-mediated cytotoxicity against tumor cells [13].
TLRs are poised to have a dual role in tumor biology
[14,15]. In one way, they are potent activators of the nu-
clear factor (NF)-kB pathway [16]. NF-kB regulates the
transcription of a number of antiapoptotic genes such as
bcl-2, iNOS, c-FLIP, inhibitor of apoptosis, and TRAF mole-
cules [17]. Therefore, they can promote growth of tumors
such as lung cancers [18], colorectal cancers [19], ovarian
cancers [20], renal cell carcinomas [21], and melanomas
[22]. In another way, their role in the regulation of the
innate and adaptive immune responses enables them to
contribute to therapy for cancers, such as bladder cancer.
Many studies have shown direct cytotoxicity of TLR agonists
against bladder cancer cell lines and an antitumor effect
in vivo. Ayari et al [23] reported the expression of many
TLRs in normal urothelium and maintenance with reduced
amounts in nonmuscle-invasive bladder tumors Normal
urothelium expressed TLR5 weakly; TLR2, TLR3, and TLR7
moderately; and TLR4 and TLR9 strongly.
We performed a series of preliminary studies on BCG
treatment of UC cells and showed that TLR2, TLR3, TLR5,
Figure 3. (A) Phagocytic index of TSGH8301 cells after being stimulated by 0.5e5 mg/mL BCG for 12 hours, 24 hours, and 48
hours (pZ 0.05). (BeD) Changes of beclin 1, ATG2, and LC3 activities involved in phagocytosis after BCG (0.05 mg/mL and 0.5 mg/
mL for 24 hours) treatment of TSGH8301 cells. (EeG) Activation of IRAK2, IRAK4, and caspase 8 after BCG (0.05 mg/mL and 0.5 mg/
mL for 24 hours) treatment in TSGH8301 cells. BCGZ Bacille Calmette-Guerin.
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and TLR7 increased in UC cells after BCG stimulation. In a
further study, we demonstrated that BCG can directly kill
UC cells in vitro with activation of TLR4, TLR7, and TLR9
proteins through the caspase 8 signaling pathway (data not
shown). In this study, we found that BCG can kill UC cells in
a dose-dependent manner and assumed that an alternative
specific pathway may be involved in the cytotoxicity of UC
cells caused by BCG, in addition to its direct killing effect.
Therefore, we speculated that TLRs, especially TLR7, may
play an important role in BCG cytotoxicity. Ayari et al [23]
reported that normal urothelium expressed TLR7 moder-
ately; in the current study, we noted that overexpression orsecondary activation of TLR7 in UC cells by BCG was closely
related to its cytotoxicity. In addition to the higher
expression of TLR7 intrinsically in low-grade UC cells, such
as TSGH8301 and TCC9202, either in mRNA or in protein
levels, TLR7 overexpression after BCG treatment in UC cells
was confirmed in our study. We found that well-
differentiated UC cells had a higher content of TLR7,
making them more sensitive to TLR agonisteBCG treat-
ment. Hence, we hypothesize that BCG can also kill UC cells
directly through the TLR7-activated pathway, in addition to
its direct cytotoxic effect.
We next investigated the mechanism of cell death via
TLR7 activation by BCG treatment in TSGH8301 cells. BCG
Figure 4. TLR7 expression in TSGH8301 cells after treatment
with BCG (0.5 mg/mL) and TLR7-inhibitor IRS661 for 24 hours.
BCGZ Bacille Calmette-Guerin; TLR Z toll-like receptor.
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cess of phagocytosis, including beclin 1, ATG2, and LC3, in
UC cells. A reverse change in the case of bcl-2 was seen in
treatment of UC cells with a higher dosage of BCG; this
indicates that a high dosage of BCG may induce a reverse
effect on the subsequent cytotoxicity to tumor cells. Our
observation demonstrated that BCG-activated TLR7 signif-
icantly leads to activation of IRAK2 and IRAK4, both critical
signaling mediators of the TLR/IL1-R superfamily, and
production of caspase 8 in TSGH8301 cells. It is an intrinsic
apoptosis pathway rather than a typical pathway with bcl-2
reduction and caspase 3 and 9 activation.
The current study demonstrates that activation of TLR7
by BCG can lead to a proapoptotic effect with increased
phagocytic activity on UC cells. Although TLR4 was also
functionally expressed in TSGH8301 cells, TLR4 signaling
did not promote apoptotic activity of tumor cells; instead
NF-kB activity was promoted to enhance the proliferating
ability of UC cells (data not shown). The effect of TLR7
activation on the proliferation of TSGH8301 cells was
examined; we found that overexpression of TLR7 by BCG
treatment dramatically inhibits UC cellular proliferation.
These results indirectly indicate that TLR7 activity in non-
muscle invasive bladder cancer cells is highly related to
tumor behavior with inhibitory effects and on the contrary
to TLR4.
In addition to the direct killing of tumor cells through an
apoptotic pathway, TLR activation will also promote the
maturation of immune cells and the production of cytokines
such as interleukin-12 within the host, which signals naive T
cells to mature into Type 1 helper T cells [24]. Although
TLRs are more heavily expressed in normal urothelial cells,
their expression and activity persist in tumor cells, offering
the possibility of therapeutic use of TLR ligands. In recent
years, three TLR agonists have been approved by the Food
and Drug Administration for use in humans: BCG, mono-
phosphoryl lipid A, and imiquimod [25,26]. Cherfils-Vicini
et al [27] have reported that TLR7 and TLR8 agonists have
been shown to increase the resistance of cultured nonsmall
cell lung cancer cells to chemotherapy, an effect that fol-
lowed the activation of an MYD88-NFkB signaling axisresulting in the upregulation of antiapoptotic bcl-2 pro-
teins. The success of TLR-mediated BCG immunotherapy for
nonmuscle invasive bladder cancers, such as TLR7-induced
apoptotic pathway proved in our study, suggests that
alternative TLR-based immunotherapies might still be suc-
cessful for these cancers. In this study, the direct cyto-
toxicity of BCG to UC cells has been reconfirmed and TLR7-
related apoptotic pathway enhancement has been
demonstrated.
Conclusion
Our results indicated that the intrinsic expression of TLR7 in
UC cells may be useful as a predictor of BCG therapy, and
the upregulation of TLR7 using agonists can be considered
as effective therapeutic alternatives for treating superficial
bladder cancer in the future.
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